Related references
Note: Only part of the references are listed.American Society of Hematology 2019 guidelines for immune thrombocytopenia
Cindy Neunert et al.
BLOOD ADVANCES (2019)
Splenectomy for immune thrombocytopenia: down but not out
Shruti Chaturvedi et al.
BLOOD (2018)
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Wojciech Jurczak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia
Renchi Yang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice
Michael Steurer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review
Jiaxing Zhang et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
Adrian Newland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study
Michael D. Tarantino et al.
LANCET (2016)
Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
Li Wang et al.
SCIENTIFIC REPORTS (2016)
Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity
Ann Janssens et al.
ACTA HAEMATOLOGICA (2015)
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
John D. Grainger et al.
LANCET (2015)
Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
James B. Bussel et al.
PEDIATRIC BLOOD & CANCER (2015)
Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
Yeo-Kyeoung Kim et al.
BLOOD RESEARCH (2015)
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults
David Gomez-Almaguer et al.
BLOOD (2014)
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
James B. Bussel et al.
BLOOD (2014)
High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia
Markus G. Seidel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients
Anil Kumar Tripathi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital
I. Marquinez-Alonso et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Pathogenesis of immune thrombocytopenia
Douglas B. Cines et al.
PRESSE MEDICALE (2014)
Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia
Soames Boyle et al.
BLOOD (2013)
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
Francesco Rodeghiero et al.
BLOOD (2013)
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)
James B. Bussel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Romiplostim as early treatment for refractory primary immune thrombocytopenia
Anne Contis et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care
David J. Kuter et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
Yukari Shirasugi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia
Y. Tomiyama et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Romiplostim in children with chronic refractory ITP: randomized placebo controlled study
Mohsen Saleh Elalfy et al.
ANNALS OF HEMATOLOGY (2011)
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
James B. Bussel et al.
BLOOD (2011)
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial
Yukari Shirasugi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Gregory Cheng et al.
LANCET (2011)
Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)
Miguel A. Sanz et al.
VALUE IN HEALTH (2011)
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura
Yan Zeng et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.
David J. Kuter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
The ITP syndrome: pathogenic and clinical diversity
Douglas B. Cines et al.
BLOOD (2009)
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials
James N. George et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function
Joseph A. Erhardt et al.
EXPERIMENTAL HEMATOLOGY (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
James B. Bussel et al.
LANCET (2009)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura
Adrian Newland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
CL Erickson-Miller et al.
EXPERIMENTAL HEMATOLOGY (2005)
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP
R McMillan et al.
BLOOD (2004)
AMG531 stimulates megakaryopoiesis in vitro by binding to Mp1
VC Broudy et al.
CYTOKINE (2004)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.
YF Cheng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
